Forced degradation studies: an essential tool for the formulation development of vaccines
暂无分享,去创建一个
Lillian Li | Manvi Hasija | Nausheen Rahman | Salvador F. Ausar | S. Ausar | M. Hasija | Nausheen Rahman | Lillian Li
[1] Ronald T Borchardt,et al. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. , 2006, Journal of pharmaceutical sciences.
[2] N. Pujar,et al. Study of Detergent‐Mediated Liberation of Hepatitis B Virus‐like Particles from S. cerevisiae Homogenate: Identifying a Framework for the Design of Future‐Generation Lipoprotein Vaccine Processes , 2008, Biotechnology progress.
[3] David R. Olsen,et al. Stabilization of proteins by recombinant human gelatins. , 2007, Journal of pharmaceutical sciences.
[4] J. Haensler. Liposomal adjuvants: preparation and formulation with antigens. , 2010, Methods in molecular biology.
[5] A. Fane,et al. Some factors determining protein aggregation during ultrafiltration. , 1993, Biotechnology and bioengineering.
[6] M. Hanna,et al. Time-dependent aggregation of reconstituted BCG vaccine. , 1994, The Journal of urology.
[7] Bernard Metz,et al. Reduction of animal use in human vaccine quality control: opportunities and problems. , 2002, Vaccine.
[8] W. Habig. Potency testing of bacterial vaccines for human use. , 1993, Veterinary Microbiology.
[9] M. Manning,et al. Flow imaging: moving toward best practices for subvisible particle quantitation in protein products. , 2013, Journal of pharmaceutical sciences.
[10] C. Wallis,et al. Effect of pH on Thermal Stabilization of Oral Poliovirus Vaccine by Magnesium Chloride , 1963, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[11] M. Corbel,et al. Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM(197) conjugate vaccines. , 2001, Vaccine.
[12] Andrea Hanefeld,et al. Relevant shaking stress conditions for antibody preformulation development. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[13] H. Doyle,et al. Altered immunogenicity of isoaspartate containing proteins , 2007, Autoimmunity.
[14] B. Yan,et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. , 2009, Journal of pharmaceutical sciences.
[15] D. Volkin,et al. Formulation, stability, and delivery of live attenuated vaccines for human use. , 1999, Critical reviews in therapeutic drug carrier systems.
[16] M. Mosca,et al. Effect of membrane composition on lipid oxidation in liposomes. , 2011, Chemistry and physics of lipids.
[17] Stephen Naylor,et al. The role of mass spectrometry in vaccine development. , 2001, Vaccine.
[18] S. Ausar,et al. High-throughput screening of stabilizers for Respiratory Syncytial Virus: Identification of stabilizers and their effects on the conformational thermostability of viral particles , 2007, Human vaccines.
[19] T. Krell,et al. Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry , 2005, Biotechnology and applied biochemistry.
[20] P. Kolhe,et al. Protein and solute distribution in drug substance containers during frozen storage and post‐thawing: A tool to understand and define freezing–thawing parameters in biotechnology process development , 2011, Biotechnology progress.
[21] L. Chedid,et al. Current status of immunological adjuvants. , 1986, Annual review of immunology.
[22] C Russell Middaugh,et al. Physical stabilization of Norwalk virus-like particles. , 2008, Journal of pharmaceutical sciences.
[23] G. Marius Clore,et al. Recombinant-derived interleukin-1α stabilized against specific deamidation , 1987 .
[24] S. Singh,et al. Effect of antimicrobial preservatives on partial protein unfolding and aggregation. , 2013, Journal of pharmaceutical sciences.
[25] S. Ausar,et al. Analysis of the thermal and pH stability of human respiratory syncytial virus. , 2005, Molecular pharmaceutics.
[26] C. Jones,et al. Physicochemical and immunological studies on the stability of free and microsphere-encapsulated tetanus toxoid in vitro. , 1996, Vaccine.
[27] Hennessey Jp,et al. Simultaneous evaluation of molecular size and antigenic stability of PNEUMOVAX 23, a multivalent pneumococcal polysaccharide vaccine. , 2000 .
[28] C. Frasch. Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges. , 2009, Vaccine.
[29] Tim J Kamerzell,et al. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. , 2011, Advanced drug delivery reviews.
[30] Nigel Jenkins,et al. Post-translational Modifications of Recombinant Proteins: Significance for Biopharmaceuticals , 2008, Molecular biotechnology.
[31] Michael J. Pikal,et al. Protein Stability During Freezing: Separation of Stresses and Mechanisms of Protein Stabilization , 2007, Pharmaceutical development and technology.
[32] P. Domingues,et al. Separation of peroxidation products of diacyl-phosphatidylcholines by reversed-phase liquid chromatography-mass spectrometry. , 2005, Biomedical chromatography : BMC.
[33] R. Sitrin,et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. , 1999, Vaccine.
[34] D. Brems,et al. Inverse Relationship of Protein Concentration and Aggregation , 2002, Pharmaceutical Research.
[35] R. K. Evans,et al. Development of stable liquid formulations for adenovirus-based vaccines. , 2004, Journal of pharmaceutical sciences.
[36] Kevin Harper,et al. Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines. , 2011, Journal of pharmaceutical sciences.
[37] S. Ausar,et al. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. , 2012, Vaccine.
[38] A. Klibanov,et al. The secondary structure and aggregation of lyophilized tetanus toxoid. , 1996, Journal of pharmaceutical sciences.
[39] P. Jurkiewicz,et al. Biophysics of lipid bilayers containing oxidatively modified phospholipids: insights from fluorescence and EPR experiments and from MD simulations. , 2012, Biochimica et biophysica acta.
[40] A. Fane,et al. Effect of membrane morphology and operation on protein deposition in ultrafiltration membranes , 1995, Biotechnology and bioengineering.
[41] A. Gronenborn,et al. Recombinant-derived interleukin-1 alpha stabilized against specific deamidation. , 1987, Protein Engineering.
[42] Leonard A. Smith,et al. Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. , 2007, Vaccine.
[43] C. Muller,et al. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens. , 2004, Vaccine.
[44] Hanns-Christian Mahler,et al. Forced degradation of therapeutic proteins. , 2012, Journal of pharmaceutical sciences.
[45] S. Joshi,et al. Spectroscopic methods for the physical characterization and formulation of nonviral gene delivery systems. , 2008, Methods in molecular biology.
[46] J. Carpenter,et al. Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. , 2009, Journal of pharmaceutical sciences.
[47] Brian M. Murphy,et al. Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.
[48] B. Chang,et al. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. , 1996, Journal of pharmaceutical sciences.
[49] T. Vedvick,et al. Conformational Stability and Disassembly of Norwalk Virus-like Particles , 2006, Journal of Biological Chemistry.
[50] J L Cleland,et al. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. , 1998, Journal of pharmaceutical sciences.
[51] S. Singh,et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. , 2010, Journal of pharmaceutical sciences.
[52] Dexiang Chen,et al. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. , 2011, Journal of pharmaceutical sciences.
[53] G. Sanyal,et al. Analysis of vaccine stability. , 1996, Developments in biological standardization.
[54] C. Spickett,et al. Chemistry of phospholipid oxidation. , 2012, Biochimica et biophysica acta.
[55] C. Hutcheon,et al. Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant. , 2006, Vaccine.
[56] S. Joshi,et al. Biophysical and stabilization studies of the Chlamydia trachomatis mouse pneumonitis major outer membrane protein. , 2009, Molecular Pharmaceutics.
[57] M. Festing. Reduction in animal use in the production and testing of biologicals. , 1999, Developments in biological standardization.
[58] R. Borchardt,et al. Chemical Pathways of Peptide Degradation. I. Deamidation of Adrenocorticotropic Hormone , 1990, Pharmaceutical Research.
[59] C. Russell Middaugh,et al. Stabilization of measles virus for vaccine formulation , 2008, Human vaccines.
[60] A. Hinman,et al. Haemophilus influenzae type B conjugate vaccine , 1988 .
[61] L. Peek,et al. Effects of Adsorption to Aluminum Salt Adjuvants on the Structure and Stability of Model Protein Antigens* , 2005, Journal of Biological Chemistry.
[62] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[63] S. Joshi,et al. Physical characterization and formulation development of a recombinant pneumolysoid protein-based pneumococcal vaccine. , 2013, Journal of pharmaceutical sciences.
[64] John F. Carpenter,et al. Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.
[65] Vincent J. Sullivan,et al. Evaluation of the effect of syringe surfaces on protein formulations. , 2011, Journal of pharmaceutical sciences.
[66] Diwakar Shukla,et al. Understanding the synergistic effect of arginine and glutamic acid mixtures on protein solubility. , 2011, The journal of physical chemistry. B.
[67] M. Slifka,et al. Development of a new hydrogen peroxide–based vaccine platform , 2012, Nature Medicine.
[68] Gideon Kersten,et al. The Potential of Physicochemical and Immunochemical Assays to Replace Animal Tests in the Quality Control of Toxoid Vaccines , 2007, Alternatives to laboratory animals : ATLA.
[69] D. Volkin,et al. Degradative covalent reactions important to protein stability , 1997, Molecular biotechnology.
[70] Debra Kristensen,et al. Opportunities and challenges of developing thermostable vaccines , 2009, Expert review of vaccines.
[71] S. Joshi,et al. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. , 2011, Journal of pharmaceutical sciences.
[72] R. Borchardt,et al. Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.
[73] Bruce A Kerwin,et al. Protect from light: photodegradation and protein biologics. , 2007, Journal of pharmaceutical sciences.
[74] A. Rosenberg,et al. Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.
[75] R. Borchardt,et al. Chemical Pathways of Peptide Degradation. VII. Solid State Chemical Instability of an Aspartyl Residue in a Model Hexapeptide , 1994, Pharmaceutical Research.
[76] B Demple,et al. Repair of oxidative damage to DNA: enzymology and biology. , 1994, Annual review of biochemistry.
[77] J. Hennessey,et al. Simultaneous evaluation of molecular size and antigenic stability of PNEUMOVAX 23, a multivalent pneumococcal polysaccharide vaccine. , 2000, Developments in Biologicals.
[78] T. Hoover,et al. Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity , 2007, Proteins.
[79] Chung C. Hsu,et al. Effect of high shear on proteins , 2000, Biotechnology and bioengineering.
[80] S. N. Timasheff,et al. Protein-solvent preferential interactions, protein hydration, and the modulation of biochemical reactions by solvent components , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[81] R. Kennedy,et al. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. , 2011, Biochemical and biophysical research communications.
[82] T. Arakawa,et al. Mechanisms of protein aggregation. , 2009, Current pharmaceutical biotechnology.
[83] M. Longo,et al. Trehalose maintains phase separation in an air-dried binary lipid mixture. , 2003, Biophysical journal.
[84] R. Borchardt,et al. Chemical Pathways of Peptide Degradation. III. Effect of Primary Sequence on the Pathways of Deamidation of Asparaginyl Residues in Hexapeptides , 1990, Pharmaceutical Research.
[85] R. K. Evans,et al. Analysis of plasmid DNA from a pharmaceutical perspective. , 1998, Journal of pharmaceutical sciences.
[86] P. Hotez,et al. Advances in vaccines against neglected tropical diseases , 2012, Human vaccines & immunotherapeutics.
[87] A. Klibanov,et al. Moisture‐induced aggregation of lyophilized proteins in the solid state , 1991, Biotechnology and bioengineering.
[88] D. Volkin,et al. Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine. , 1997, Journal of pharmaceutical sciences.
[89] B. Lina,et al. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly. , 2000, Biologicals : journal of the International Association of Biological Standardization.
[90] Maya S. Salnikova,et al. Influence of formulation pH and suspension state on freezing-induced agglomeration of aluminum adjuvants. , 2012, Journal of Pharmacy and Science.
[91] J. Kuo,et al. Replacement of a labile aspartyl residue increases the stability of human epidermal growth factor. , 1990, Biochemistry.
[92] Jared S. Bee,et al. Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies. , 2009, Journal of pharmaceutical sciences.
[93] D. Pogocki,et al. Conformational Flexibility Controls Proton Transfer between the Methionine Hydroxy Sulfuranyl Radical and the N-Terminal Amino Group in Thr−(X)n−Met Peptides , 2001 .
[94] D. Volkin,et al. Preformulation studies--The next advance in aluminum adjuvant-containing vaccines. , 2010, Vaccine.
[95] C. Wiethoff,et al. Thermal stability of vaccines. , 2003, Journal of pharmaceutical sciences.